niraparib

This page shows the latest niraparib news and features for those working in and with pharma, biotech and healthcare.

CHMP backs AZ’s Lynparza for ovarian cancer maintenance

in the face of competition from newer market entrants Rubraca (rucaparib) from Clovis Oncology and Johnson &Johnson/Tesaro’s Zejula (niraparib).

AZ and Merck & Co get FDA breast cancer nod for Lynparza

Johnson &Johnson/Tesaro’s Zejula (niraparib).
J&J files would-be prostate cancer blockbuster in US

Along with apalutamide J&J is also intending to file its PARP inhibitor Zejula (niraparib), which is already approved for ovarian cancer as a treatment for advanced prostate cancer in men
CHMP backs maintenance therapy for Tesaro's Zejula

Oncology. The EMA's advisory committee backed Zejula (niraparib) on the strength of data showing it can improved progression-free survival (PFS) compared to placebo in ovarian cancer patients.
Lynparza approval sets up tighter bout with PARP rivals

inhibitor category in the US, and particularly Tesaro's Zejula (niraparib) which was approved as a maintenance therapy in March on the back of strong clinical data.
BMS and Clovis join forces in PARP combo race

Merck previously put a combination of Opdivo and Tesaro's new PARP inhibitor Zejula (niraparib) through its paces. ... Credit Suisse previously predicted that Lynparza will lead the PARP inhibitor market in 2020, with sales of $1.6bn and just ahead of

More from news
Approximately 3 fully matching, plus 19 partially matching documents found.

Deal Watch April 2016

Licensing one indication for a new product is unusual not least of all because of potential pricing issues if niraparib is launched by different companies at different prices. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer

No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer. ... The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study with women with relapsed platinum-sensitive high-grade ovarian cancer.
No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer

No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer. ... The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study with women with relapsed platinum-sensitive high-grade ovarian cancer.

More from PMHub
Approximately 2 fully matching, plus 0 partially matching documents found.

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Add my company

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...